Patent Document ID: 9296716
Application ID: 14360081
Patent Flag: 1

Claim One:
1. A method of treating prostate cancer comprising administering to a patient in need thereof a compound of general formula (I), a tautomer thereof, a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein A is selected from the group consisting of: wherein A′ is selected from the group consisting of: wherein at least one of A or A′ is optionally substituted one or more times with at least one of C 1 -C 10 alkyl, C(═O)H, C(═O)OH, C(═O)OR 1 , C(═O)NH 2 , C(═O)NHR 1 , C(═O)NR 1 R 2 , C(═O)R 1 , CH 2 F, CHF 2 , CF 3 , C≡N, OH, OR 1 , OC(═O)R 1 , OC(═O)OR 1 , OC(═O)NH 2 , OC(═O)NHR 1 , OC(═O)NR 1 R 2 , NH 2 , NHR 1 , NR 1 R 2 , N(H)C(═O)R 1 , N(R 1 )C(═O)R 2 , N(H)C(═O)OR 1 , N(R 1 )C(═O)OR 2 , N(H)C(═O)NH 2 , N(R 1 )C(═O)NH 2 , N(H)C(═O)NHR 1 , N(R 1 )C(═O)NHR 2 , N(H)C(═O)NR 1 R 2 , N(R 1 )C(═O)NR 2 R 3 , NO 2 , SH, SR 1 , S(═O)R 1 , S(═O) 2 R 1 , SO 3 H, OP(O)(OH)(OH), OP(O)(OH)(OR′), OP(O)(OR 1 )(OR 2 ), H, Hal, CH 2 Hal; CH 2 OH, CH 2 SH, CH 2 NH 2 , CH 2 NH 2 , CH 2 COOH, CH 2 COOR 1 , NHC(NH)NH 2 , wherein Hal is Cl, Br, F, and I, and wherein R 1 , R 2 and R 3 are the same or different and are independently selected from the group consisting of C 1 -C 20 aliphatic, C 3 -C 20 cycloaliphatic and combinations thereof; wherein Y is OH, SH or NH 2 ; and R 4 is H or methyl; with the proviso that the compound is not 3-hydroxy-N′-(4-hydroxy-3,5-dimethoxybenzylidene)-2-naphthohydrazide (MDG489), N′-(3-methoxybenzylidene)naphtho[2,1-b]furan-2-carbohydrazide (MDG505), 3-hydroxy-N′-(2-hydroxy-3-chlorobenzylidene)-2-naphthohydrazide (MDG618), 3-hydroxy-N′-[(1E)-1-(2-hydroxy-5-chlorophenyl)ethylidene]-2-naphthohydrazide (MDG621) and 3-hydroxy-N′-benzylidene-2-naphthohydrazide (MDG628).